Go Pro
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free KRMD Stock Alerts

KORU Medical Systems (KRMD) Financials

KORU Medical Systems logo
$4.49 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$4.48 -0.01 (-0.31%)
As of 07/2/2026 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for KORU Medical Systems

Annual Income Statements for KORU Medical Systems

This table shows KORU Medical Systems' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/29/2016 2/29/2016 2/28/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.78 0.78 -0.53 0.56 -1.18 -4.56 -8.66 -14 -6.07 -2.64
Consolidated Net Income / (Loss)		 0.78 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Net Income / (Loss) Continuing Operations		 0.78 0.78 -0.53 0.56 -1.18 -4.56 -8.66 -14 -6.07 -2.64
Total Pre-Tax Income 		1.14 1.14 -0.78 0.70 1.19 -6.36 -11 -9.77 -6.06 -2.62
Total Operating Income		 1.18 1.18 -0.74 0.59 -1.25 -7.03 -11 -10 -6.45 -2.97
Total Gross Profit		 7.60 7.60 7.57 15 15 14 15 17 21 26
Total Revenue		 12 12 12 23 24 23 28 29 34 41
Operating Revenue		 12 12 12 23 24 23 28 29 34 41
Total Cost of Revenue		 4.64 4.64 4.72 8.31 9.24 9.72 13 12 12 16
Operating Cost of Revenue		 4.64 4.64 4.72 8.31 9.24 9.72 13 12 12 16
Total Operating Expenses		 6.42 6.42 8.31 14 16 21 26 27 28 29
Selling, General & Admin Expense		 5.94 5.94 7.77 9.77 12 18 21 20 22 23
Research & Development Expense		 0.21 0.21 0.24 0.74 1.30 2.47 4.96 5.74 5.26 4.39
Depreciation Expense		 0.27 0.27 0.30 0.34 0.42 0.46 0.59 0.87 0.89 0.81
Total Other Income / (Expense), net		 -0.04 -0.04 -0.04 0.11 0.06 -0.02 0.11 0.50 0.38 0.36
Interest & Investment Income		 - - - - - - - - 0.44 0.29
Other Income / (Expense), net		 -0.04 -0.04 -0.04 0.11 0.06 -0.02 0.11 0.50 -0.06 0.06
Income Tax Expense		 0.36 0.36 -0.24 0.13 -0.02 -1.80 -2.01 3.97 0.00 0.02
Basic Earnings per Share		 $0.02 $0.02 ($0.01) $0.01 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Weighted Average Basic Shares Outstanding		 37.99M 37.99M 37.83M 38.78M 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Diluted Earnings per Share		 $0.02 $0.02 ($0.01) $0.01 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Weighted Average Diluted Shares Outstanding		 37.99M 37.99M 37.88M 39.06M 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Weighted Average Basic & Diluted Shares Outstanding		 37.97M - 37.82M - 44.48M 44.67M 45.52M 45.71M 45.96M 46.37M

Quarterly Income Statements for KORU Medical Systems

This table shows KORU Medical Systems' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.37 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81
Consolidated Net Income / (Loss)		 -1.37 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81
Net Income / (Loss) Continuing Operations		 -1.37 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81
Total Pre-Tax Income 		-1.67 -2.02 -1.94 -0.99 -1.58 -1.56 -1.17 -0.19 -0.78 -0.48 -0.81
Total Operating Income		 -1.79 -2.20 -1.96 -1.19 -1.70 -1.59 -1.25 -0.31 -0.87 -0.55 -0.86
Total Gross Profit		 4.34 4.33 5.10 5.48 5.19 5.56 6.05 6.48 6.26 6.82 7.23
Total Revenue		 7.00 7.19 8.20 8.43 8.18 8.84 9.64 10 10 11 12
Operating Revenue		 7.00 7.19 8.20 8.43 8.18 8.84 9.64 10 10 11 12
Total Cost of Revenue		 2.66 2.85 3.09 2.95 2.99 3.28 3.59 3.72 4.14 4.08 4.53
Operating Cost of Revenue		 2.66 2.85 3.09 2.95 2.99 3.28 3.59 3.72 4.14 4.08 4.53
Total Operating Expenses		 6.13 6.53 7.06 6.67 6.89 7.15 7.29 6.79 7.13 7.36 8.10
Selling, General & Admin Expense		 4.62 5.01 5.36 5.32 5.13 5.83 5.96 5.38 5.99 6.04 6.58
Research & Development Expense		 1.29 1.29 1.48 1.13 1.53 1.11 1.11 1.19 0.93 1.14 1.32
Depreciation Expense		 0.22 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20
Total Other Income / (Expense), net		 0.12 0.18 0.03 0.20 0.12 0.03 0.08 0.12 0.09 0.06 0.06
Interest & Investment Income		 - - - - 0.11 - 0.07 - 0.07 - 0.08
Other Income / (Expense), net		 0.12 0.18 0.03 0.20 0.01 0.03 0.01 0.12 0.01 -0.15 -0.02
Income Tax Expense		 -0.30 5.45 0.00 0.00 0.00 0.00 0.00 0.02 -0.00 0.00 0.00
Basic Earnings per Share		 ($0.03) ($0.17) $0.04 - - ($0.04) ($0.03) - - - ($0.02)
Weighted Average Basic Shares Outstanding		 45.64M 45.60M 45.71M 45.86M 45.84M 45.80M 45.98M 46.23M 46.32M 46.19M 46.36M
Diluted Earnings per Share		 ($0.03) ($0.17) $0.04 $0.02 $0.03 ($0.04) ($0.03) $0.00 $0.02 ($0.11) ($0.02)
Weighted Average Diluted Shares Outstanding		 45.64M 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.19M 46.24M 46.19M 46.36M
Weighted Average Basic & Diluted Shares Outstanding		 45.67M 45.71M 45.76M 45.86M 45.84M 45.96M 46.14M 46.23M 46.32M 46.37M 45.93M

Annual Cash Flow Statements for KORU Medical Systems

This table details how cash moves in and out of KORU Medical Systems' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/29/2016 2/29/2016 2/28/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.64 1.64 -0.89 2.13 21 -1.98 -7.93 -5.93 -1.90 -0.71
Net Cash From Operating Activities		 1.91 1.91 -0.33 0.32 -0.74 -4.32 -5.40 -4.89 -0.32 0.46
Net Cash From Continuing Operating Activities		 1.91 1.91 -0.33 0.32 -0.74 -4.32 -5.40 -4.89 -0.32 0.46
Net Income / (Loss) Continuing Operations		 0.78 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Consolidated Net Income / (Loss)		 0.78 0.78 -0.53 0.56 -1.21 -4.56 -8.66 -14 -6.07 -2.64
Depreciation Expense		 0.27 0.27 0.30 0.34 0.42 0.46 0.59 0.87 0.89 0.81
Non-Cash Adjustments To Reconcile Net Income		 0.09 0.09 0.16 1.15 2.88 2.71 3.29 2.81 2.88 2.61
Changes in Operating Assets and Liabilities, net		 0.74 0.74 -0.29 -1.73 -2.87 -2.93 -0.62 5.17 1.97 -0.32
Net Cash From Investing Activities		 -0.19 -0.19 -0.42 1.31 -1.04 -0.37 -2.80 -0.81 -1.33 -0.95
Net Cash From Continuing Investing Activities		 -0.19 -0.19 -0.42 1.31 -1.04 -0.37 -2.80 -0.81 -1.33 -0.95
Purchase of Property, Plant & Equipment		 -0.12 -0.12 -0.20 -0.20 -0.92 -0.35 -2.76 -0.78 -1.30 -0.93
Acquisitions		 -0.08 -0.08 -0.21 -0.22 -0.14 -0.03 -0.04 -0.03 -0.04 -0.02
Sale of Property, Plant & Equipment		 0.01 0.01 - 0.22 0.03 0.01 - 0.00 0.01 0.01
Net Cash From Financing Activities		 -0.08 -0.08 -0.14 0.50 23 2.71 0.28 -0.22 -0.25 -0.22
Net Cash From Continuing Financing Activities		 -0.08 -0.08 -0.14 0.50 23 2.71 0.28 -0.22 -0.25 -0.22
Repayment of Debt		 - - - 0.00 - 0.51 -0.08 0.57 - 0.41
Other Financing Activities, net		 - 0.00 -0.04 -0.00 -0.01 -0.00 -0.05 -0.78 -0.74 -0.63
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.03 0.01 0.03 0.05 0.07 0.06
Cash Income Taxes Paid		 0.26 0.26 0.19 0.13 0.32 0.00 0.00 0.00 0.00 0.01

Quarterly Cash Flow Statements for KORU Medical Systems

This table details how cash moves in and out of KORU Medical Systems' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -0.95 0.71 -0.66 -0.36 -1.65 0.77 -0.85 -0.68 0.41 0.41 -0.10
Net Cash From Operating Activities		 -1.17 1.10 -0.35 0.01 -0.92 0.94 -0.24 -0.46 0.07 1.09 0.01
Net Cash From Continuing Operating Activities		 -1.19 1.10 -0.35 0.01 -0.92 0.94 -0.24 -0.46 0.07 1.09 0.01
Net Income / (Loss) Continuing Operations		 -1.37 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81
Consolidated Net Income / (Loss)		 -1.37 -7.47 -1.94 -0.99 -1.58 -1.56 -1.17 -0.21 -0.78 -0.49 -0.81
Depreciation Expense		 0.22 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20
Non-Cash Adjustments To Reconcile Net Income		 0.68 0.38 0.69 0.61 0.86 0.72 0.70 0.42 0.63 0.87 0.68
Changes in Operating Assets and Liabilities, net		 -0.72 7.95 0.66 0.17 -0.44 1.57 0.01 -0.88 0.01 0.53 -0.06
Net Cash From Investing Activities		 -0.21 -0.21 -0.13 -0.15 -1.10 0.05 -0.45 -0.03 -0.05 -0.42 -0.09
Net Cash From Continuing Investing Activities		 -0.21 -0.21 -0.13 -0.15 -1.10 0.05 -0.45 -0.03 -0.05 -0.42 -0.09
Purchase of Property, Plant & Equipment		 -0.21 -0.20 -0.13 -0.12 -1.08 0.04 -0.44 -0.03 -0.05 -0.41 -0.05
Acquisitions		 -0.00 -0.01 0.00 -0.02 -0.02 -0.00 -0.00 - - -0.02 -0.04
Net Cash From Financing Activities		 0.44 -0.18 -0.18 -0.23 0.37 -0.22 -0.16 -0.19 0.40 -0.26 -0.03
Net Cash From Continuing Financing Activities		 0.44 -0.18 -0.18 -0.23 0.37 -0.22 -0.16 -0.19 0.40 -0.26 -0.03
Repayment of Debt		 0.47 0.53 -0.16 -0.16 - -0.53 -0.13 -0.14 0.68 - 0.00
Other Financing Activities, net		 -0.02 -0.71 -0.03 -0.07 -0.43 0.31 -0.03 -0.05 -0.28 -0.26 -0.03
Cash Interest Paid		 0.01 0.02 0.01 0.01 0.03 0.03 0.01 0.00 0.03 0.02 0.00

Annual Balance Sheets for KORU Medical Systems

This table presents KORU Medical Systems' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 2/29/2016 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 8.39 9.28 14 40 41 42 28 27 28
Total Current Assets		 7.12 7.93 12 38 37 30 20 19 20
Cash & Equivalents		 4.20 3.97 5.87 27 25 17 11 9.58 8.87
Accounts Receivable		 1.35 1.86 3.23 2.57 4.31 4.53 4.07 6.00 6.53
Inventories, net		 1.04 1.66 2.39 6.83 6.11 6.40 3.48 2.80 3.68
Prepaid Expenses		 0.27 0.17 0.39 0.81 1.57 1.46 1.22 0.75 0.91
Plant, Property, & Equipment, net		 1.00 0.84 0.61 1.17 1.11 3.89 3.84 4.29 4.47
Total Noncurrent Assets		 0.28 0.52 1.39 1.23 2.87 8.64 4.37 3.80 3.74
Intangible Assets		 0.25 0.48 0.81 0.84 0.81 0.79 0.75 0.73 0.68
Other Noncurrent Operating Assets		 0.03 0.03 0.39 0.26 0.12 3.89 3.61 3.07 3.06
Total Liabilities & Shareholders' Equity		 8.39 9.28 14 40 41 42 28 27 28
Total Liabilities		 1.28 1.61 2.65 3.76 4.79 11 8.11 10 11
Total Current Liabilities		 1.11 1.59 2.41 3.67 4.79 6.96 4.45 7.20 8.19
Accounts Payable		 0.31 0.45 0.57 0.62 1.23 2.39 0.98 1.65 2.27
Accrued Expenses		 0.50 0.66 1.30 2.61 2.71 2.89 1.71 3.92 4.83
Current Employee Benefit Liabilities		 0.15 0.33 0.19 0.29 0.16 0.54 0.46 0.81 0.53
Other Current Liabilities		 0.02 0.02 0.14 0.14 0.19 0.70 0.99 0.55 0.57
Total Noncurrent Liabilities		 0.17 0.03 0.24 0.10 0.00 4.05 3.65 3.20 2.96
Capital Lease Obligations		 0.04 0.00 - - 0.00 0.39 0.32 0.20 0.08
Other Noncurrent Operating Liabilities		 - - 0.24 0.10 0.00 3.65 3.34 3.00 2.88
Total Equity & Noncontrolling Interests		 7.12 7.67 11 36 37 31 20 17 17
Total Preferred & Common Equity		 7.12 7.67 11 36 37 31 20 17 17
Total Common Equity		 7.12 7.67 11 36 37 31 20 17 17
Common Stock		 4.37 4.62 6.72 36 41 45 48 50 53
Retained Earnings		 3.02 3.39 4.86 3.65 -0.91 -9.57 -23 -29 -32
Treasury Stock		 -0.25 -0.34 -0.34 -3.84 -3.84 -3.84 -3.84 -3.88 -3.88

Quarterly Balance Sheets for KORU Medical Systems

This table presents KORU Medical Systems' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 35 28 27 27 27 26 27 29
Total Current Assets		 22 19 19 19 19 18 19 21
Cash & Equivalents		 11 11 10 8.81 8.74 8.05 8.46 8.77
Accounts Receivable		 4.86 4.68 5.85 5.24 6.27 5.09 5.52 6.32
Inventories, net		 4.68 3.15 2.59 3.93 3.28 3.95 4.41 4.48
Prepaid Expenses		 1.37 0.83 0.47 0.96 0.71 0.49 1.03 1.03
Plant, Property, & Equipment, net		 3.82 3.76 3.68 4.55 4.53 4.37 4.24 4.34
Total Noncurrent Assets		 9.85 4.27 4.26 3.91 3.68 3.57 3.45 3.67
Intangible Assets		 0.76 0.74 0.75 0.75 0.72 0.70 0.68 0.71
Other Noncurrent Operating Assets		 3.64 3.53 3.51 3.16 2.97 2.87 2.77 2.96
Total Liabilities & Shareholders' Equity		 35 28 27 27 27 26 27 29
Total Liabilities		 7.92 8.38 8.60 9.66 11 8.99 11 12
Total Current Liabilities		 4.22 4.85 5.14 6.32 7.80 6.05 7.83 8.85
Accounts Payable		 0.95 1.77 1.60 1.67 2.01 1.09 1.87 2.64
Accrued Expenses		 1.46 1.46 2.14 2.79 3.98 3.64 4.63 5.27
Current Employee Benefit Liabilities		 0.39 0.52 0.44 0.77 1.04 0.69 0.46 0.39
Other Current Liabilities		 0.96 0.94 0.95 0.69 0.63 0.63 0.54 0.56
Total Noncurrent Liabilities		 3.70 3.53 3.46 3.33 3.07 2.94 2.80 2.82
Capital Lease Obligations		 0.32 0.29 0.26 0.23 0.17 0.15 0.12 0.05
Other Noncurrent Operating Liabilities		 3.38 3.24 3.20 3.10 2.90 2.79 2.69 2.77
Total Equity & Noncontrolling Interests		 27 19 19 18 16 17 16 17
Total Preferred & Common Equity		 27 19 19 18 16 17 16 17
Total Common Equity		 27 19 19 18 16 17 16 17
Common Stock		 47 48 49 49 51 51 52 55
Retained Earnings		 -16 -25 -26 -28 -31 -31 -32 -33
Treasury Stock		 -3.84 -3.84 -3.88 -3.88 -3.88 -3.88 -3.88 -5.55

Annual Metrics And Ratios for KORU Medical Systems

This table displays calculated financial ratios and metrics derived from KORU Medical Systems' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 2/28/2015 2/29/2016 2/28/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 38,081,667.00 38,006,667.00 37,749,081.00 38,216,932.00 39,501,870.00 43,942,888.00 44,561,160.00 45,279,948.00 45,669,362.00 - 46,322,655.00
DEI Adjusted Shares Outstanding		 38,081,667.00 38,006,667.00 37,749,081.00 38,216,932.00 39,501,870.00 43,942,888.00 44,561,160.00 45,279,948.00 45,669,362.00 - 46,322,655.00
DEI Earnings Per Adjusted Shares Outstanding		 0.02 0.02 -0.01 - 0.01 -0.03 -0.10 -0.19 -0.30 - -0.06
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 29.27% 0.00% 0.38% 41.16% 0.00% 4.38% -2.84% 18.76% 2.23% 17.98% 22.23%
EBITDA Growth		 15.97% 5.16% -130.87% 433.08% -30.25% -170.78% -797.07% -53.26% 11.74% 41.87% 62.65%
EBIT Growth		 6.70% 6.60% -167.61% 251.90% -40.83% -271.49% -489.93% -51.52% 8.45% 37.96% 55.30%
NOPAT Growth		 14.64% 0.66% -163.67% 277.66% -47.32% -368.32% -286.39% -53.37% 4.74% 37.23% 53.89%
Net Income Growth		 7.06% 0.00% -168.34% 270.20% 0.00% -314.77% -276.45% -89.82% -58.65% 55.85% 56.52%
EPS Growth		 0.00% 0.00% -150.00% 300.00% 0.00% -400.00% -233.33% -90.00% -57.89% 56.67% 53.85%
Operating Cash Flow Growth		 -13.44% 131.79% -117.32% 546.20% 0.00% -331.84% -481.11% -25.12% 9.47% 93.47% 244.63%
Free Cash Flow Firm Growth		 77.31% 228.48% -212.58% 116.04% -287.56% -300.35% -63.24% -36.93% 81.67% -39.57% 3.23%
Invested Capital Growth		 -8.91% 0.00% 0.00% 7.81% 44.84% 64.80% 32.04% 26.30% -35.56% -18.90% 7.11%
Revenue Q/Q Growth		 7.79% -1.75% -15.49% 17.73% 0.00% 0.00% 11.56% 3.16% -0.55% 5.17% 5.26%
EBITDA Q/Q Growth		 2.06% 61.92% -124.21% 134.13% 0.00% -290.37% -17.69% -2.27% 4.63% 7.93% 25.33%
EBIT Q/Q Growth		 -8.49% 93.19% -142.58% 261.73% 0.00% 0.00% -16.19% -2.87% 3.86% 7.09% 20.37%
NOPAT Q/Q Growth		 -4.93% 75.21% -143.83% 79.93% 0.00% 0.00% -15.60% -3.84% 2.97% 8.62% 25.96%
Net Income Q/Q Growth		 -9.39% 87.86% -144.34% 116.49% 0.00% 0.00% -5.40% -11.72% -66.52% 49.32% 28.94%
EPS Q/Q Growth		 -33.33% 0.00% -150.00% 100.00% 0.00% 0.00% 0.00% -5.56% -87.50% 50.00% 64.71%
Operating Cash Flow Q/Q Growth		 -44.04% 0.00% 73.00% 10.78% 0.00% -141.50% 18.72% 27.53% -5.15% -96.72% 50.49%
Free Cash Flow Firm Q/Q Growth		 117.71% -4.74% -75.89% -82.25% 79.82% -191.81% 2.92% 18.27% 75.33% -192.27% -54.36%
Invested Capital Q/Q Growth		 -16.20% 0.00% 0.40% 0.00% -8.75% 17.77% 3.89% -13.06% -45.52% -19.38% -2.34%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.47% 62.08% 61.57% 62.29% 64.13% 61.78% 58.62% 55.09% 58.59% 63.40% 62.26%
EBITDA Margin		 12.79% 11.80% -3.63% 8.56% 4.48% -3.04% -28.02% -36.16% -31.22% -15.38% -5.10%
Operating Margin		 10.20% 9.65% -5.99% 6.71% 2.53% -5.19% -29.93% -38.65% -36.01% -19.16% -7.23%
EBIT Margin		 9.56% 9.36% -6.30% 6.78% 3.01% -4.94% -29.99% -38.27% -34.27% -18.02% -7.07%
Profit (Net Income) Margin		 6.70% 6.39% -4.35% 5.25% 2.44% -5.01% -19.42% -31.05% -48.18% -18.03% -6.41%
Tax Burden Percent		 70.09% 68.52% 68.88% 77.37% 81.04% -101.49% 71.69% 81.13% 140.59% 100.05% 100.84%
Interest Burden Percent		 99.95% 99.70% 100.24% 100.00% 100.00% -100.00% 90.34% 100.00% 100.00% 100.00% 89.92%
Effective Tax Rate		 29.91% 31.48% 0.00% 22.63% 18.96% -1.49% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 28.39% 0.00% -30.00% 25.24% 10.47% -17.93% -47.97% -57.13% -59.30% -52.44% -26.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 29.93% 0.00% -29.07% 25.04% 8.85% -18.30% -49.34% -51.74% -11.53% -36.87% -19.85%
Return on Net Nonoperating Assets (RNNOA)		 -16.16% 0.00% 16.05% -14.29% -8.77% 12.81% 35.41% 31.59% 6.12% 19.80% 10.49%
Return on Equity (ROE)		 12.24% 0.00% -13.95% 10.95% 1.70% -5.11% -12.56% -25.54% -53.18% -32.64% -15.58%
Cash Return on Invested Capital (CROIC)		 37.72% 0.00% -230.00% 17.72% -26.16% -66.87% -75.59% -80.37% -16.05% -31.57% -32.94%
Operating Return on Assets (OROA)		 14.72% 0.00% -8.35% 11.87% 10.03% -4.44% -17.35% -25.53% -27.61% -21.78% -10.50%
Return on Assets (ROA)		 10.31% 0.00% -5.76% 9.19% 8.13% -4.51% -11.24% -20.71% -38.82% -21.79% -9.52%
Return on Common Equity (ROCE)		 12.24% 0.00% -13.95% 10.95% 1.70% -5.11% -12.56% -25.54% -53.18% -32.64% -15.58%
Return on Equity Simple (ROE_SIMPLE)		 10.58% 0.00% -6.98% 10.16% 5.02% -3.35% -12.50% -27.65% -67.51% -36.08% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.80 0.81 -0.52 0.90 0.47 -1.27 -4.92 -7.55 -7.19 -4.51 -2.08
NOPAT Margin		 7.15% 6.61% -4.19% 5.19% 2.05% -5.27% -20.95% -27.05% -25.21% -13.41% -5.06%
Net Nonoperating Expense Percent (NNEP)		 -1.54% 0.00% -0.93% 0.20% 1.61% 0.37% 1.37% -5.38% -47.77% -15.58% -6.23%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -34.26% -26.10% -12.15%
Cost of Revenue to Revenue		 40.53% 37.92% 38.43% 37.71% 35.87% 38.22% 41.38% 44.91% 41.41% 36.60% 37.74%
SG&A Expenses to Revenue		 42.58% 48.52% 63.18% 52.41% 42.19% 49.75% 76.04% 73.87% 71.41% 64.29% 56.84%
R&D to Revenue		 4.16% 1.69% 1.93% 1.39% 3.20% 5.36% 10.53% 17.77% 20.14% 15.63% 10.67%
Operating Expenses to Revenue		 49.27% 52.43% 67.56% 55.58% 61.60% 66.97% 88.54% 93.74% 94.60% 82.56% 69.48%
Earnings before Interest and Taxes (EBIT)		 1.08 1.15 -0.77 1.18 0.70 -1.19 -7.05 -11 -9.77 -6.06 -2.91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.44 1.45 -0.45 1.49 1.04 -0.73 -6.58 -10 -8.90 -5.18 -2.10
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.75 0.00 1.61 0.00 22.96 7.32 3.66 5.16 5.51 10.50 15.79
Price to Tangible Book Value (P/TBV)		 1.82 0.00 1.72 0.00 24.73 7.49 3.75 5.29 5.72 10.97 16.45
Price to Revenue (P/Rev)		 1.11 1.02 1.01 0.00 11.14 10.94 5.69 5.79 3.93 5.24 6.54
Price to Earnings (P/E)		 16.59 15.92 0.00 0.00 457.07 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 6.03% 6.28% 0.00% 0.00% 0.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.99 0.00 2.37 0.00 46.98 26.83 9.32 9.84 10.66 21.72 31.54
Enterprise Value to Revenue (EV/Rev)		 0.72 0.00 0.66 0.00 10.88 9.81 4.63 5.20 3.55 4.97 6.33
Enterprise Value to EBITDA (EV/EBITDA)		 5.61 0.00 0.00 0.00 243.17 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 7.51 0.00 0.00 0.00 361.96 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 10.04 0.00 0.00 0.00 531.12 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.77 0.00 0.00 0.00 786.22 0.00 0.00 0.00 0.00 0.00 563.02
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.03 0.03 0.00
Long-Term Debt to Equity		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00
Financial Leverage		 -0.54 0.00 -0.55 -0.57 -0.99 -0.70 -0.72 -0.61 -0.53 -0.54 -0.53
Leverage Ratio		 1.19 0.00 1.21 1.19 1.24 1.14 1.12 1.23 1.37 1.50 1.64
Compound Leverage Factor		 1.19 0.00 1.21 1.19 1.24 -1.14 1.01 1.23 1.37 1.50 1.47
Debt to Total Capital		 0.63% 0.00% 0.05% 0.00% 0.00% 0.00% 1.37% 2.57% 3.01% 2.74% 0.46%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.37% 1.35% 1.50% 1.57% 0.00%
Long-Term Debt to Total Capital		 0.63% 0.00% 0.05% 0.00% 0.00% 0.00% 0.00% 1.23% 1.51% 1.17% 0.46%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.37% 0.00% 99.95% 100.00% 100.00% 100.00% 98.63% 97.43% 96.99% 97.26% 99.54%
Debt to EBITDA		 0.03 0.00 -0.01 0.00 0.00 0.00 -0.08 -0.08 -0.07 -0.09 -0.04
Net Debt to EBITDA		 -3.07 0.00 9.49 0.00 0.00 0.00 3.77 1.64 1.22 1.76 4.19
Long-Term Debt to EBITDA		 0.03 0.00 -0.01 0.00 0.00 0.00 0.00 -0.04 -0.04 -0.04 -0.04
Debt to NOPAT		 0.06 0.00 -0.01 0.00 0.00 0.00 -0.10 -0.11 -0.09 -0.11 -0.04
Net Debt to NOPAT		 -5.49 0.00 8.22 0.00 0.00 0.00 5.05 2.20 1.51 2.02 4.23
Long-Term Debt to NOPAT		 0.06 0.00 -0.01 0.00 0.00 0.00 0.00 -0.05 -0.04 -0.04 -0.04
Altman Z-Score		 9.00 0.00 6.99 0.00 61.64 43.84 17.66 8.97 7.69 9.69 14.51
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.43 0.00 5.00 5.70 4.94 10.24 7.79 4.28 4.55 2.66 2.44
Quick Ratio		 5.25 0.00 3.85 4.22 3.78 8.15 6.19 3.15 3.49 2.16 1.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1.07 3.51 -3.95 0.63 -1.19 -4.75 -7.75 -11 -1.95 -2.72 -2.63
Operating Cash Flow to CapEx		 139.68% 1,769.17% -163.26% 508.44% 0.00% -83.00% -1,281.32% -195.74% -624.89% -24.81% 49.95%
Free Cash Flow to Firm to Interest Expense		 2,086.80 1,028.62 -2,094.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 1,613.47 561.20 -175.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 458.37 529.48 -283.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.54 0.00 1.32 1.75 3.34 0.90 0.58 0.67 0.81 1.21 1.48
Accounts Receivable Turnover		 7.27 0.00 6.60 10.56 0.00 8.33 6.82 6.31 6.63 6.68 6.57
Inventory Turnover		 4.90 0.00 2.85 3.48 0.00 2.00 1.50 2.00 2.39 3.92 4.79
Fixed Asset Turnover		 12.25 0.00 14.70 20.48 0.00 27.17 20.66 11.17 7.38 8.28 9.39
Accounts Payable Turnover		 16.44 0.00 10.40 14.41 0.00 15.43 10.49 6.92 7.01 9.38 7.93
Days Sales Outstanding (DSO)		 50.23 0.00 55.28 34.58 0.00 43.84 53.48 57.85 55.07 54.63 55.59
Days Inventory Outstanding (DIO)		 74.45 0.00 128.16 104.94 0.00 182.06 242.87 182.27 152.78 93.14 76.20
Days Payable Outstanding (DPO)		 22.20 0.00 35.11 25.32 0.00 23.65 34.78 52.73 52.03 38.90 46.06
Cash Conversion Cycle (CCC)		 102.48 0.00 148.33 114.20 0.00 202.25 261.57 187.39 155.82 108.87 85.74
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.70 0.00 3.44 3.70 5.37 8.84 12 15 9.50 7.71 8.25
Invested Capital Turnover		 3.97 0.00 7.16 4.86 5.11 3.40 2.29 2.11 2.35 3.91 5.15
Increase / (Decrease) in Invested Capital		 -0.26 -2.70 3.44 0.27 1.66 3.48 2.83 3.07 -5.24 -1.80 0.55
Enterprise Value (EV)		 8.07 0.00 8.15 0.00 252 237 109 145 101 167 260
Market Capitalization		 12 12 12 0.00 258 265 134 162 112 176 269
Book Value per Share		 $0.19 $0.00 $0.20 $0.23 $0.28 $0.82 $0.82 $0.69 $0.45 $0.37 $0.37
Tangible Book Value per Share		 $0.18 $0.00 $0.19 $0.21 $0.26 $0.80 $0.80 $0.67 $0.43 $0.35 $0.35
Total Capital		 7.16 0.00 7.67 8.96 11 36 37 32 21 17 17
Total Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.51 0.83 0.63 0.47 0.08
Total Long-Term Debt		 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.39 0.32 0.20 0.08
Net Debt		 -4.42 0.00 -4.23 -5.26 -5.87 -27 -25 -17 -11 -9.11 -8.79
Capital Expenditures (CapEx)		 0.59 0.11 0.20 0.29 -0.02 0.90 0.34 2.76 0.78 1.29 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.55 0.00 2.11 2.19 3.60 6.54 7.70 5.87 4.63 2.62 2.92
Debt-free Net Working Capital (DFNWC)		 6.01 0.00 6.34 7.45 9.48 34 33 23 16 12 12
Net Working Capital (NWC)		 6.01 0.00 6.34 7.45 9.48 34 33 23 16 12 12
Net Nonoperating Expense (NNE)		 0.05 0.03 0.02 -0.01 -0.09 -0.06 -0.36 1.11 6.55 1.55 0.56
Net Nonoperating Obligations (NNO)		 -4.42 0.00 -4.23 -5.26 -5.87 -27 -25 -17 -11 -9.11 -8.79
Total Depreciation and Amortization (D&A)		 0.36 0.30 0.33 0.31 0.34 0.46 0.46 0.59 0.87 0.89 0.81
Debt-free, Cash-free Net Working Capital to Revenue		 13.76% 0.00% 17.13% 12.63% 15.56% 27.07% 32.79% 21.03% 16.25% 7.79% 7.11%
Debt-free Net Working Capital to Revenue		 53.45% 0.00% 51.60% 42.92% 40.91% 140.05% 140.65% 83.44% 56.51% 36.26% 28.68%
Net Working Capital to Revenue		 53.45% 0.00% 51.60% 42.92% 40.91% 140.05% 138.48% 81.89% 55.41% 35.46% 28.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Adjusted Weighted Average Basic Shares Outstanding		 37.63M 37.99M 37.83M 0.00 0.00 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Adjusted Diluted Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 ($0.03) ($0.10) ($0.19) ($0.30) ($0.13) ($0.06)
Adjusted Weighted Average Diluted Shares Outstanding		 37.63M 37.99M 37.88M 0.00 0.00 41.93M 44.39M 45.00M 45.60M 45.80M 46.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.02 ($0.01) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.01M 0.00 37.82M 0.00 0.00 44.48M 44.67M 45.52M 45.71M 45.96M 46.37M
Normalized Net Operating Profit after Tax (NOPAT)		 0.80 0.81 -0.52 0.90 3.24 0.83 -4.92 -7.55 -7.19 -4.51 -2.08
Normalized NOPAT Margin		 7.15% 6.61% -4.19% 5.19% 14.00% 3.45% -20.95% -27.05% -25.21% -13.41% -5.06%
Pre Tax Income Margin		 9.56% 9.33% -6.32% 6.78% 3.01% 4.94% -27.09% -38.27% -34.27% -18.02% -6.36%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 2,099.70 335.87 -410.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 1,570.66 237.24 -273.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 944.60 304.15 -518.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 415.56 205.52 -380.97 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 3.22% 10.29% -18.20% 0.00% 0.50% -288.71% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for KORU Medical Systems

This table displays calculated financial ratios and metrics derived from KORU Medical Systems' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 45,639,081.00 45,669,362.00 45,710,500.00 45,764,225.00 45,855,328.00 - 45,957,115.00 46,140,996.00 46,234,957.00 46,322,655.00 46,370,432.00
DEI Adjusted Shares Outstanding		 45,639,081.00 45,669,362.00 45,710,500.00 45,764,225.00 45,855,328.00 - 45,957,115.00 46,140,996.00 46,234,957.00 46,322,655.00 46,370,432.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.03 -0.16 -0.04 -0.02 -0.03 - -0.03 0.00 -0.02 -0.01 -0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -9.76% -2.16% 10.89% 21.54% 16.80% 23.00% 17.53% 20.93% 27.17% 23.27% 22.10%
EBITDA Growth		 -8.99% 19.44% 38.58% 73.26% -0.93% 24.87% 40.04% 102.59% 55.79% 68.91% 32.44%
EBIT Growth		 -11.45% 16.24% 35.22% 68.06% -1.52% 22.89% 35.98% 80.83% 49.66% 62.91% 28.35%
NOPAT Growth		 -17.10% 12.50% 35.84% 63.03% 4.90% 27.67% 36.52% 73.77% 49.06% 65.58% 30.53%
Net Income Growth		 -11.64% -277.70% 19.70% 60.39% -15.53% 79.09% 39.76% 79.08% 50.79% 68.81% 30.80%
EPS Growth		 0.00% -466.67% 180.00% 140.00% 200.00% 76.47% -175.00% -100.00% -33.33% 50.00% 33.33%
Operating Cash Flow Growth		 44.47% -17.93% 92.56% 107.36% 21.36% -14.33% 31.51% -4,161.23% 107.08% 16.51% 106.17%
Free Cash Flow Firm Growth		 74.47% 176.72% 202.84% 269.98% 485.72% -81.55% -100.59% -104.47% -92.52% -236.22% -1,759.62%
Invested Capital Growth		 2.83% -35.56% -51.84% -49.14% -45.19% -18.90% -9.42% 1.31% -11.59% 7.11% 3.54%
Revenue Q/Q Growth		 0.97% 2.61% 14.08% 2.83% -2.97% 8.05% 9.01% 5.81% 2.03% 4.74% 7.98%
EBITDA Q/Q Growth		 49.62% -23.41% 4.91% 54.78% -90.18% 0.46% 39.11% 102.11% -3,344.90% 19.50% -32.33%
EBIT Q/Q Growth		 46.11% -21.12% 4.20% 48.93% -71.31% 1.43% 34.42% 83.75% -349.94% 17.79% -26.69%
NOPAT Q/Q Growth		 44.46% -22.70% 10.75% 39.22% -42.89% 6.68% 21.67% 74.89% -177.52% 36.95% -58.09%
Net Income Q/Q Growth		 45.18% -445.66% 74.07% 48.93% -59.89% 1.24% 25.30% 82.26% -276.07% 37.42% -65.77%
EPS Q/Q Growth		 40.00% -466.67% 123.53% -50.00% 50.00% -33.33% 86.36% -100.00% 0.00% -650.00% 81.82%
Operating Cash Flow Q/Q Growth		 -663.19% 193.36% -131.61% 103.27% -8,251.28% 201.70% -125.27% -93.85% 114.22% 1,572.51% -98.66%
Free Cash Flow Firm Q/Q Growth		 60.08% 313.60% 117.07% -8.17% -9.41% -89.79% -106.97% -592.58% 251.57% -286.13% 4.82%
Invested Capital Q/Q Growth		 4.28% -45.52% -7.98% -2.73% 12.38% -19.38% 2.78% 8.79% -1.92% -2.34% -0.65%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 62.00% 60.27% 62.25% 65.00% 63.40% 62.94% 62.75% 63.52% 60.22% 62.57% 61.47%
EBITDA Margin		 -20.74% -24.95% -20.79% -9.14% -17.92% -15.24% -10.61% 0.20% -6.23% -4.79% -5.87%
Operating Margin		 -25.57% -30.58% -23.93% -14.14% -20.82% -17.98% -12.92% -3.07% -8.34% -5.02% -7.35%
EBIT Margin		 -23.83% -28.12% -23.62% -11.73% -20.71% -17.63% -12.86% -1.86% -8.20% -6.43% -7.55%
Profit (Net Income) Margin		 -19.54% -103.90% -23.62% -11.73% -19.33% -17.66% -12.10% -2.03% -7.48% -4.47% -6.86%
Tax Burden Percent		 82.01% 369.44% 100.00% 100.00% 100.00% 100.19% 100.00% 109.16% 99.98% 100.97% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 93.33% 100.00% 94.10% 100.00% 91.26% 68.78% 90.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -29.85% -50.35% -36.51% -24.18% -34.54% -49.23% -38.08% -9.24% -25.33% -18.11% -27.62%
ROIC Less NNEP Spread (ROIC-NNEP)		 -28.95% -7.14% -31.39% -22.75% -30.26% -44.73% -34.95% -9.37% -23.22% -16.95% -25.26%
Return on Net Nonoperating Assets (RNNOA)		 12.33% 3.79% 14.13% 10.49% 12.17% 24.02% 18.52% 4.82% 10.99% 8.96% 13.02%
Return on Equity (ROE)		 -17.52% -46.57% -22.38% -13.69% -22.37% -25.21% -19.56% -4.42% -14.34% -9.15% -14.60%
Cash Return on Invested Capital (CROIC)		 -45.87% -16.05% 22.24% 25.52% 21.81% -31.57% -38.25% -40.96% -18.91% -32.94% -25.99%
Operating Return on Assets (OROA)		 -17.51% -22.66% -21.06% -11.42% -21.12% -21.31% -16.50% -2.59% -11.75% -9.55% -11.70%
Return on Assets (ROA)		 -14.36% -83.71% -21.06% -11.42% -19.71% -21.35% -15.52% -2.83% -10.72% -6.63% -10.63%
Return on Common Equity (ROCE)		 -17.52% -46.57% -22.38% -13.69% -22.37% -25.21% -19.56% -4.42% -14.34% -9.15% -14.60%
Return on Equity Simple (ROE_SIMPLE)		 -30.08% 0.00% -69.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.25 -1.54 -1.37 -0.83 -1.19 -1.11 -0.87 -0.22 -0.61 -0.38 -0.61
NOPAT Margin		 -17.90% -21.41% -16.75% -9.90% -14.58% -12.59% -9.05% -2.15% -5.84% -3.52% -5.15%
Net Nonoperating Expense Percent (NNEP)		 -0.90% -43.22% -5.12% -1.43% -4.28% -4.49% -3.14% 0.13% -2.11% -1.16% -2.35%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.33% -7.02% -4.40% -6.49% -6.44% -5.23% -1.31% -3.59% -2.24% -3.57%
Cost of Revenue to Revenue		 38.00% 39.73% 37.75% 35.00% 36.60% 37.06% 37.25% 36.48% 39.78% 37.43% 38.53%
SG&A Expenses to Revenue		 66.03% 69.76% 65.35% 63.10% 62.69% 65.92% 61.85% 52.81% 57.63% 55.44% 55.95%
R&D to Revenue		 18.47% 17.92% 18.00% 13.45% 18.75% 12.61% 11.57% 11.72% 8.97% 10.51% 11.19%
Operating Expenses to Revenue		 87.58% 90.85% 86.18% 79.14% 84.22% 80.92% 75.68% 66.59% 68.57% 67.59% 68.82%
Earnings before Interest and Taxes (EBIT)		 -1.67 -2.02 -1.94 -0.99 -1.69 -1.56 -1.24 -0.19 -0.85 -0.70 -0.89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.45 -1.79 -1.70 -0.77 -1.47 -1.35 -1.02 0.02 -0.65 -0.52 -0.69
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.49 5.51 5.64 6.48 7.06 10.50 7.14 10.00 10.76 15.79 11.84
Price to Tangible Book Value (P/TBV)		 4.62 5.72 5.87 6.75 7.37 10.97 7.47 10.44 11.22 16.45 12.36
Price to Revenue (P/Rev)		 4.30 3.93 3.68 3.94 3.91 5.24 3.33 4.48 4.53 6.54 4.63
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6.49 10.66 11.15 13.06 12.24 21.72 13.67 18.25 20.00 31.54 23.36
Enterprise Value to Revenue (EV/Rev)		 3.95 3.55 3.33 3.60 3.66 4.97 3.09 4.27 4.33 6.33 4.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 550.23 563.02 268.15
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 32.59 34.50 39.75 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.03 0.02 0.01 0.04 0.03 0.02 0.01 0.03 0.00 0.00
Long-Term Debt to Equity		 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00
Financial Leverage		 -0.43 -0.53 -0.45 -0.46 -0.40 -0.54 -0.53 -0.51 -0.47 -0.53 -0.52
Leverage Ratio		 1.30 1.37 1.34 1.35 1.39 1.50 1.54 1.50 1.59 1.64 1.68
Compound Leverage Factor		 1.30 1.37 1.34 1.35 1.30 1.50 1.45 1.50 1.45 1.13 1.52
Debt to Total Capital		 2.78% 3.01% 2.29% 1.37% 3.44% 2.74% 1.87% 0.87% 2.67% 0.46% 0.27%
Short-Term Debt to Total Capital		 1.65% 1.50% 0.81% 0.00% 2.19% 1.57% 0.82% 0.00% 1.98% 0.00% 0.00%
Long-Term Debt to Total Capital		 1.12% 1.51% 1.47% 1.37% 1.25% 1.17% 1.05% 0.87% 0.69% 0.46% 0.27%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.23% 96.99% 97.71% 98.63% 96.56% 97.26% 98.13% 99.13% 97.33% 99.54% 99.73%
Debt to EBITDA		 -0.08 -0.07 -0.06 -0.05 -0.11 -0.09 -0.06 -0.04 -0.16 -0.04 -0.03
Net Debt to EBITDA		 1.07 1.22 1.32 1.78 1.43 1.76 1.71 2.18 2.85 4.19 4.93
Long-Term Debt to EBITDA		 -0.03 -0.04 -0.04 -0.05 -0.04 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03
Debt to NOPAT		 -0.11 -0.09 -0.07 -0.05 -0.13 -0.11 -0.08 -0.04 -0.16 -0.04 -0.03
Net Debt to NOPAT		 1.35 1.51 1.62 2.04 1.66 2.02 2.10 2.33 2.85 4.23 4.81
Long-Term Debt to NOPAT		 -0.04 -0.04 -0.04 -0.05 -0.05 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03
Altman Z-Score		 9.95 8.58 7.91 8.75 7.87 10.24 6.50 11.30 10.21 14.77 10.60
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 5.14 4.55 4.01 3.77 2.99 2.66 2.44 2.91 2.48 2.44 2.33
Quick Ratio		 3.70 3.49 3.19 3.17 2.22 2.16 1.92 2.17 1.78 1.88 1.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.73 3.70 8.04 7.38 6.69 0.68 -0.05 -0.33 0.50 -0.93 -0.89
Operating Cash Flow to CapEx		 -555.08% 559.45% -260.53% 9.12% -85.26% 0.00% -53.55% -1,597.63% 124.72% 268.47% 31.76%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.74 0.81 0.89 0.97 1.02 1.21 1.28 1.40 1.43 1.48 1.55
Accounts Receivable Turnover		 5.40 6.63 5.95 5.81 6.33 6.68 6.41 6.74 7.27 6.57 6.87
Inventory Turnover		 2.11 2.39 2.38 2.94 2.76 3.92 3.99 4.15 3.53 4.79 4.25
Fixed Asset Turnover		 8.03 7.38 7.65 8.23 7.64 8.28 8.46 9.16 8.89 9.39 9.75
Accounts Payable Turnover		 10.58 7.01 7.11 7.29 9.09 9.38 6.76 10.09 8.31 7.93 7.08
Days Sales Outstanding (DSO)		 67.59 55.07 61.37 62.87 57.63 54.63 56.97 54.16 50.23 55.59 53.11
Days Inventory Outstanding (DIO)		 172.65 152.78 153.19 124.19 132.04 93.14 91.56 87.86 103.39 76.20 85.94
Days Payable Outstanding (DPO)		 34.51 52.03 51.30 50.05 40.14 38.90 53.97 36.16 43.92 46.06 51.52
Cash Conversion Cycle (CCC)		 205.72 155.82 163.25 137.02 149.53 108.87 94.56 105.86 109.71 85.74 87.53
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 17 9.50 8.74 8.51 9.56 7.71 7.92 8.62 8.45 8.25 8.20
Invested Capital Turnover		 1.67 2.35 2.18 2.44 2.37 3.91 4.21 4.30 4.34 5.15 5.37
Increase / (Decrease) in Invested Capital		 0.48 -5.24 -9.41 -8.22 -7.88 -1.80 -0.82 0.11 -1.11 0.55 0.28
Enterprise Value (EV)		 113 101 98 111 117 167 108 157 169 260 192
Market Capitalization		 123 112 108 121 125 176 117 165 177 269 200
Book Value per Share		 $0.60 $0.45 $0.42 $0.41 $0.39 $0.37 $0.36 $0.36 $0.36 $0.37 $0.36
Tangible Book Value per Share		 $0.58 $0.43 $0.40 $0.39 $0.37 $0.35 $0.34 $0.34 $0.34 $0.35 $0.35
Total Capital		 28 21 20 19 18 17 17 17 17 17 17
Total Debt		 0.78 0.63 0.45 0.26 0.63 0.47 0.31 0.15 0.45 0.08 0.05
Total Long-Term Debt		 0.32 0.32 0.29 0.26 0.23 0.20 0.17 0.15 0.12 0.08 0.05
Net Debt		 -9.99 -11 -10 -10 -8.17 -9.11 -8.42 -7.91 -8.01 -8.79 -8.72
Capital Expenditures (CapEx)		 0.21 0.20 0.13 0.12 1.08 -0.04 0.44 0.03 0.05 0.41 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.16 4.63 3.97 3.77 4.20 2.62 2.60 3.47 3.46 2.92 2.97
Debt-free Net Working Capital (DFNWC)		 18 16 15 14 13 12 11 12 12 12 12
Net Working Capital (NWC)		 17 16 15 14 13 12 11 12 12 12 12
Net Nonoperating Expense (NNE)		 0.11 5.93 0.56 0.15 0.39 0.45 0.29 -0.01 0.17 0.10 0.20
Net Nonoperating Obligations (NNO)		 -9.99 -11 -10 -10 -8.17 -9.11 -8.42 -7.91 -8.01 -8.79 -8.72
Total Depreciation and Amortization (D&A)		 0.22 0.23 0.23 0.22 0.23 0.21 0.22 0.21 0.20 0.18 0.20
Debt-free, Cash-free Net Working Capital to Revenue		 24.96% 16.25% 13.52% 12.24% 13.13% 7.79% 7.41% 9.43% 8.85% 7.11% 6.86%
Debt-free Net Working Capital to Revenue		 62.53% 56.51% 50.42% 46.17% 40.65% 36.26% 32.31% 31.29% 30.51% 28.68% 27.13%
Net Working Capital to Revenue		 60.90% 55.41% 49.88% 46.17% 39.40% 35.46% 31.92% 31.29% 29.65% 28.68% 27.13%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.03) ($0.17) ($0.04) ($0.02) ($0.03) ($0.04) $0.03 $0.00 $0.00 $0.00 ($0.02)
Adjusted Weighted Average Basic Shares Outstanding		 45.64M 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.23M 46.32M 46.19M 46.36M
Adjusted Diluted Earnings per Share		 ($0.03) ($0.17) ($0.04) ($0.02) ($0.03) ($0.04) $0.03 $0.00 $0.02 ($0.11) ($0.02)
Adjusted Weighted Average Diluted Shares Outstanding		 45.64M 45.60M 45.71M 45.81M 45.85M 45.80M 45.98M 46.19M 46.24M 46.19M 46.36M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 45.67M 45.71M 45.76M 45.86M 45.84M 45.96M 46.14M 46.23M 46.32M 46.37M 45.93M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.25 -1.54 -1.37 -0.83 -1.19 -1.11 -0.87 -0.22 -0.61 -0.38 -0.61
Normalized NOPAT Margin		 -17.90% -21.41% -16.75% -9.90% -14.58% -12.59% -9.05% -2.15% -5.84% -3.52% -5.15%
Pre Tax Income Margin		 -23.83% -28.12% -23.62% -11.73% -19.33% -17.63% -12.10% -1.86% -7.48% -4.43% -6.86%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

KORU Medical Systems (NASDAQ: KRMD) showed meaningful revenue growth in Q1 2026, but profitability and cash generation remain uneven. Revenue rose to $11.8 million from $9.6 million in Q1 2025, while gross profit also improved. However, the company still posted an operating loss and a net loss, and operating cash flow was only marginally positive after a quarter of much stronger cash generation in late 2025.

  • Revenue growth accelerated in Q1 2026. Sales increased 22.1% year over year to $11.76 million from $9.64 million in Q1 2025.
  • Gross profit improved alongside revenue. Gross profit rose to $7.23 million from $6.05 million a year ago, showing the company is scaling the top line.
  • Balance sheet remains solid on a near-term liquidity basis. Cash and equivalents were $8.77 million at March 31, 2026, with current assets of $20.59 million versus current liabilities of $8.85 million.
  • Equity increased year over year. Total common equity rose to $16.92 million from $16.35 million in Q1 2025.
  • Operating cash flow was slightly positive in Q1 2026. The company generated $14.7 thousand from operations, a better result than the cash burn seen in Q1 2025.
  • Q4 2025 showed a much stronger cash quarter than Q1 2026. Operating cash flow was $1.09 million in Q4 2025, suggesting quarterly results can be lumpy.
  • Shares outstanding have drifted higher. Weighted average diluted shares were 46.36 million in Q1 2026 versus 45.98 million in Q1 2025, which can dilute per-share gains.
  • Inventory and receivables remain significant working-capital items. At quarter-end, inventories were $4.48 million and accounts receivable were $6.32 million.
  • KRMD is still losing money. Q1 2026 net loss was $807 thousand, compared with a $1.17 million loss in Q1 2025 and a $487 thousand loss in Q4 2025.
  • Operating losses remain wide. The company posted an operating loss of $864.9 thousand in Q1 2026, despite higher revenue.
  • Operating expenses continue to absorb most of gross profit. SG&A was $6.58 million and R&D was $1.32 million in Q1 2026, leaving little room for bottom-line improvement.
  • Cash declined during the quarter. Net change in cash and equivalents was negative $104.4 thousand in Q1 2026.

Longer-term trend: KRMD has improved revenue from roughly $8.2 million in Q1 2024 to $11.8 million in Q1 2026, which is encouraging. But profitability has not kept pace, as operating losses have persisted across the period. The good news is that the balance sheet still provides some breathing room, with cash above debt and a current ratio comfortably above 2x. The key question for investors is whether management can convert revenue growth into sustained operating leverage.

07/05/26 03:05 PM ETAI Generated. May Contain Errors.

KORU Medical Systems Financials - Frequently Asked Questions

According to the most recent income statement we have on file, KORU Medical Systems' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

KORU Medical Systems' net income appears to be on an upward trend, with a most recent value of -$2.64 million in 2025, falling from $782.86 thousand in 2015. The previous period was -$6.07 million in 2024. See KORU Medical Systems' forecast for analyst expectations on what's next for the company.

KORU Medical Systems' total operating income in 2025 was -$2.97 million, based on the following breakdown:
  • Total Gross Profit: $25.60 million
  • Total Operating Expenses: $28.58 million

Over the last 9 years, KORU Medical Systems' total revenue changed from $12.25 million in 2015 to $41.13 million in 2025, a change of 235.8%.

KORU Medical Systems' total liabilities were at $11.15 million at the end of 2025, a 7.2% increase from 2024, and a 774.0% increase since 2015.

In the past 8 years, KORU Medical Systems' cash and equivalents has ranged from $3.97 million in 2017 to $27.32 million in 2020, and is currently $8.87 million as of their latest financial filing in 2025.

Over the last 10 years, KORU Medical Systems' book value per share changed from 0.19 in 2015 to 0.37 in 2025, a change of 96.9%.


Related Companies

Financial statements for NASDAQ:KRMD last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel